5akt - Revision history

OCA at 11:12, 10 January 2024

2024-01-10T11:12:02Z

←Older revision		Revision as of 11:12, 10 January 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AKT FirstGlance]. <br>		<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AKT FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=R4G:RESVERATROL-4-O-GLUCURONIDE'>R4G</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.35Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=R4G:RESVERATROL-4-O-GLUCURONIDE'>R4G</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5akt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5akt OCA], [https://pdbe.org/5akt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5akt RCSB], [https://www.ebi.ac.uk/pdbsum/5akt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5akt ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5akt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5akt OCA], [https://pdbe.org/5akt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5akt RCSB], [https://www.ebi.ac.uk/pdbsum/5akt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5akt ProSAT]</span></td></tr>
	</table>		</table>

OCA at 05:06, 25 May 2023

2023-05-25T05:06:47Z

←Older revision

Revision as of 05:06, 25 May 2023

OCA at 08:02, 21 May 2019

2019-05-21T08:02:09Z

←Older revision		Revision as of 08:02, 21 May 2019
Line 1:		Line 1:

	==Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide==		==Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide==
-	<StructureSection load='5akt' size='340' side='right' caption='[[5akt]], [[Resolution\|resolution]] 1.35Å' scene=''>	+	<StructureSection load='5akt' size='340' side='right'caption='[[5akt]], [[Resolution\|resolution]] 1.35Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AKT FirstGlance]. <br>		<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AKT FirstGlance]. <br>
Line 29:		Line 29:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Berni, R]]		[[Category: Berni, R]]
	[[Category: Cianci, M]]		[[Category: Cianci, M]]

OCA at 06:00, 8 March 2018

2018-03-08T06:00:54Z

←Older revision		Revision as of 06:00, 8 March 2018
Line 1:		Line 1:
		+
	==Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide==		==Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide==
	<StructureSection load='5akt' size='340' side='right' caption='[[5akt]], [[Resolution\|resolution]] 1.35Å' scene=''>		<StructureSection load='5akt' size='340' side='right' caption='[[5akt]], [[Resolution\|resolution]] 1.35Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AKT FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AKT FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=R4G:RESVERATROL-4-O-GLUCURONIDE'>R4G</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=R4G:RESVERATROL-4-O-GLUCURONIDE'>R4G</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5aks\|5aks]], [[5akv\|5akv]], [[5al0\|5al0]], [[5al8\|5al8]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5aks\|5aks]], [[5akv\|5akv]], [[5al0\|5al0]], [[5al8\|5al8]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5akt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5akt OCA], [http://pdbe.org/5akt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5akt RCSB], [http://www.ebi.ac.uk/pdbsum/5akt PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5akt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5akt OCA], [http://pdbe.org/5akt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5akt RCSB], [http://www.ebi.ac.uk/pdbsum/5akt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5akt ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 5akt" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5akt" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Transthyretin\|Transthyretin]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Berni, R]]		[[Category: Berni, R]]
	[[Category: Cianci, M]]		[[Category: Cianci, M]]
Line 34:		Line 39:
	[[Category: Fibrillogenesis inhibitor]]		[[Category: Fibrillogenesis inhibitor]]
	[[Category: Negative cooperativity]]		[[Category: Negative cooperativity]]
-	[[Category: Polyphenol metabolite]]
	[[Category: Polyphenol]]		[[Category: Polyphenol]]
		+	[[Category: Polyphenol metabolite]]
	[[Category: Transport protein]]		[[Category: Transport protein]]

OCA at 19:01, 30 November 2015

2015-11-30T19:01:08Z

←Older revision		Revision as of 19:01, 30 November 2015
Line 11:		Line 11:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/TTHY_HUMAN TTHY_HUMAN]] Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.<ref>PMID:3714052</ref>		[[http://www.uniprot.org/uniprot/TTHY_HUMAN TTHY_HUMAN]] Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.<ref>PMID:3714052</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Transthyretin (TTR) is an amyloidogenic protein, whose amyloidogenic potential is enhanced by a number of specific point mutations. The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Comparative analyses of the interaction and of the ability to protect the TTR native state for polyphenols, both stilbenoids and flavonoids, and some of their main metabolites have been carried out. A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of X-ray analysis of TTR in complex with both ligands. While revealing the ability of the two thyroxine binding sites of TTR to discriminate between different ligands, this feature has allowed us to evaluate the interactions of polyphenols with both resveratrol and thyroxine preferential binding sites, by using resveratrol and radiolabeled T4 as probes. Among flavonoids, genistein and apigenin were able to effectively displace resveratrol from its preferential binding site, while genistein also showed the ability to interact, albeit weakly, with the preferential thyroxine binding site. Several glucuronidated polyphenol metabolites did not exhibit significant competition for resveratrol and thyroxine preferential binding sites, and lacked the ability to stabilize TTR. However, resveratrol-3-O-sulphate was able to significantly protect the protein native state. A rationale for the in vitro properties found for polyphenol metabolites was provided by X-ray analysis of their complexes with TTR.
		+
		+	Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and their Metabolites.,Florio P, Folli C, Cianci M, Del Rio D, Zanotti G, Berni R J Biol Chem. 2015 Oct 14. pii: jbc.M115.690172. PMID:26468275<ref>PMID:26468275</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 5akt" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 05:32, 22 October 2015

2015-10-22T05:32:00Z

←Older revision		Revision as of 05:32, 22 October 2015
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide==
-		+	<StructureSection load='5akt' size='340' side='right' caption='[[5akt]], [[Resolution\|resolution]] 1.35Å' scene=''>
-	~~The entry~~ 5akt is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[5akt]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AKT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AKT FirstGlance]. <br>
-	~~Authors~~: ~~Florio~~, P., ~~Foll~~, C., ~~Cianci~~, M., ~~Del Rio~~, D., ~~Zanotti~~, G., ~~Berni~~, R.	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=R4G:RESVERATROL-4-O-GLUCURONIDE'>R4G</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5aks\|5aks]], [[5akv\|5akv]], [[5al0\|5al0]], [[5al8\|5al8]]</td></tr>
-	~~Description~~: ~~Transthyretin~~ binding ~~heterogeneity~~ and ~~anti-amyloidogenic activity~~ of ~~natural polyphenols~~ and ~~their metabolites~~: ~~resveratrol-4'-O-glucuronide~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5akt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5akt OCA], [http://pdbe.org/5akt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5akt RCSB], [http://www.ebi.ac.uk/pdbsum/5akt PDBsum]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/TTHY_HUMAN TTHY_HUMAN]] Defects in TTR are the cause of amyloidosis transthyretin-related (AMYL-TTR) [MIM:[http://omim.org/entry/105210 105210]]. A hereditary generalized amyloidosis due to transthyretin amyloid deposition. Protein fibrils can form in different tissues leading to amyloid polyneuropathies, amyloidotic cardiomyopathy, carpal tunnel syndrome, systemic senile amyloidosis. The disease includes leptomeningeal amyloidosis that is characterized by primary involvement of the central nervous system. Neuropathologic examination shows amyloid in the walls of leptomeningeal vessels, in pia arachnoid, and subpial deposits. Some patients also develop vitreous amyloid deposition that leads to visual impairment (oculoleptomeningeal amyloidosis). Clinical features include seizures, stroke-like episodes, dementia, psychomotor deterioration, variable amyloid deposition in the vitreous humor.<ref>PMID:11243784</ref> <ref>PMID:15735344</ref> <ref>PMID:19167329</ref> <ref>PMID:3818577</ref> <ref>PMID:3022108</ref> <ref>PMID:6651852</ref> <ref>PMID:6583672</ref> <ref>PMID:3135807</ref> <ref>PMID:1517749</ref> <ref>PMID:1932142</ref> <ref>PMID:7923855</ref> <ref>PMID:8382610</ref> <ref>PMID:8428915</ref> <ref>PMID:9733771</ref> <ref>PMID:12403615</ref> <ref>PMID:16185074</ref> <ref>PMID:16627944</ref> <ref>PMID:6487335</ref> <ref>PMID:3722385</ref> <ref>PMID:2891727</ref> <ref>PMID:2161654</ref> <ref>PMID:2363717</ref> <ref>PMID:1656975</ref> <ref>PMID:2046936</ref> <ref>PMID:1570831</ref> <ref>PMID:1734866</ref> <ref>PMID:1520326</ref> <ref>PMID:1520336</ref> <ref>PMID:1544214</ref> <ref>PMID:1351039</ref> <ref>PMID:1301926</ref> <ref>PMID:1362222</ref> <ref>PMID:1436517</ref> <ref>PMID:8352764</ref> <ref>PMID:8038017</ref> <ref>PMID:8257997</ref> <ref>PMID:8095302</ref> <ref>PMID:1997217</ref> <ref>PMID:8019560</ref> <ref>PMID:8081397</ref> <ref>PMID:7914929</ref> <ref>PMID:8133316</ref> <ref>PMID:7910950</ref> <ref>PMID:7655883</ref> <ref>PMID:7850982</ref> <ref>PMID:8579098</ref> <ref>PMID:9066351</ref> <ref>PMID:8990019</ref> <ref>PMID:9605286</ref> <ref>PMID:10036587</ref> <ref>PMID:10627135</ref> <ref>PMID:10694917</ref> <ref>PMID:10211412</ref> <ref>PMID:10439117</ref> <ref>PMID:10611950</ref> <ref>PMID:10071047</ref> <ref>PMID:10436378</ref> <ref>PMID:10842705</ref> <ref>PMID:10842718</ref> <ref>PMID:10882995</ref> <ref>PMID:11445644</ref> <ref>PMID:12557757</ref> <ref>PMID:11866053</ref> <ref>PMID:12050338</ref> <ref>PMID:12771253</ref> <ref>PMID:15214015</ref> <ref>PMID:15478468</ref> <ref>PMID:15217993</ref> <ref>PMID:17453626</ref> <ref>PMID:17577687</ref> <ref>PMID:17503405</ref> <ref>PMID:17635579</ref> Defects in TTR are a cause of hyperthyroxinemia dystransthyretinemic euthyroidal (HTDE) [MIM:[http://omim.org/entry/145680 145680]]. It is a condition characterized by elevation of total and free thyroxine in healthy, euthyroid persons without detectable binding protein abnormalities.<ref>PMID:1979335</ref> Defects in TTR are a cause of carpal tunnel syndrome type 1 (CTS1) [MIM:[http://omim.org/entry/115430 115430]]. It is a condition characterized by entrapment of the median nerve within the carpal tunnel. Symptoms include burning pain and paresthesias involving the ventral surface of the hand and fingers which may radiate proximally. Impairment of sensation in the distribution of the median nerve and thenar muscle atrophy may occur. This condition may be associated with repetitive occupational trauma, wrist injuries, amyloid neuropathies, rheumatoid arthritis.<ref>PMID:8309582</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/TTHY_HUMAN TTHY_HUMAN]] Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.<ref>PMID:3714052</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
	[[Category: Berni, R]]		[[Category: Berni, R]]
-	[[Category: Florio, P]]
-	[[Category: Foll, C]]
-	[[Category: Del Rio, D]]
	[[Category: Cianci, M]]		[[Category: Cianci, M]]
		+	[[Category: Florio, P]]
		+	[[Category: Folli, C]]
		+	[[Category: Rio, D Del]]
	[[Category: Zanotti, G]]		[[Category: Zanotti, G]]
		+	[[Category: Amyloid]]
		+	[[Category: Fibrillogenesis]]
		+	[[Category: Fibrillogenesis inhibitor]]
		+	[[Category: Negative cooperativity]]
		+	[[Category: Polyphenol metabolite]]
		+	[[Category: Polyphenol]]
		+	[[Category: Transport protein]]

OCA at 13:38, 17 June 2015

2015-06-17T13:38:23Z

←Older revision		Revision as of 13:38, 17 June 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5akt is ON HOLD	+	The entry 5akt is ON HOLD until Paper Publication

	Authors: Florio, P., Foll, C., Cianci, M., Del Rio, D., Zanotti, G., Berni, R.		Authors: Florio, P., Foll, C., Cianci, M., Del Rio, D., Zanotti, G., Berni, R.

OCA: Protected "5akt" [edit=sysop:move=sysop]

2015-03-11T11:03:34Z

Protected "5akt" [edit=sysop:move=sysop]

←Older revision

Revision as of 11:03, 11 March 2015

OCA: New page: '''Unreleased structure''' The entry 5akt is ON HOLD Authors: Florio, P., Foll, C., Cianci, M., Del Rio, D., Zanotti, G., Berni, R. Description: Transthyretin binding heterogeneity and...

2015-03-11T11:03:33Z

New page: '''Unreleased structure''' The entry 5akt is ON HOLD Authors: Florio, P., Foll, C., Cianci, M., Del Rio, D., Zanotti, G., Berni, R. Description: Transthyretin binding heterogeneity and...

New page

'''Unreleased structure'''

The entry 5akt is ON HOLD

Authors: Florio, P., Foll, C., Cianci, M., Del Rio, D., Zanotti, G., Berni, R.

Description: Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O-glucuronide
[[Category: Unreleased Structures]]
[[Category: Berni, R]]
[[Category: Florio, P]]
[[Category: Foll, C]]
[[Category: Del Rio, D]]
[[Category: Cianci, M]]
[[Category: Zanotti, G]]